Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity
Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity
复制标题
DOI：
10.1080/00365513.2017.1419372
复制
发表时间：
2018-01-01
影响因子：
2.1
通讯作者：
Farup, Per G.
中科院分区：
文献类型：
--
作者：
Aasbrenn, Martin;Valeur, Jorgen;Farup, Per G.
需要肠易激综合征（IBS）的生物标志物。在IBS受试者中已经报道了改变的粪便微生物组，并且可能是有价值的生物标志物。这项研究评估了一种新的粪便微生态失调测试的诊断特性，旨在区分IBS与健康志愿者，并比较了与IBS和病态肥胖相关的微生态失调的患病率。包括有和没有病态肥胖和IBS的受试者。用GA-map（TM）生态失调试验（Genetic Analysis AS，奥斯陆，挪威）评估粪便微生物群。试验结果为微生态失调（是/否）。在四组之间进行了比较：IBS和病态肥胖受试者（IBS+/MO+）;无IBS和病态肥胖的受试者（IBS-/MO+）; IBS受试者且无病态肥胖（IBS+/MO-）;和健康志愿者IBS+/MO+、IBS-/MO+、IBS+/MO-和IBS-/MO-组的微生态失调患病率分别为18/28（64%）、45/71（63%）、31/63（49%）和38/91（42%）。与健康志愿者相比，病态肥胖受试者（无论是否患有IBS）的微生态失调更为普遍（p值为0.04和0.006）。在无病态肥胖的受试者中用作IBS的诊断测试，阳性和阴性似然比（LR）分别为1.18（0.83-1.67）和0.87（0.65-1.18），在病态肥胖的受试者中LR分别为1.01（95%CI：0.73-1.41）和0.98（0.54-1.75）。生态失调试验不适合作为IBS的诊断试验。在统计学上，生态失调与病态肥胖显著相关，但与IBS无关。
Biomarkers for irritable bowel syndrome (IBS) are demanded. An altered faecal microbiome has been reported in subjects with IBS and could be a valuable biomarker. This study evaluated the diagnostic properties of a new test for faecal dysbiosis, designed to distinguish IBS from healthy volunteers and compared the prevalence rates of dysbiosis related to IBS and morbid obesity. Subjects with and without morbid obesity and IBS were included. The faecal microbiota was assessed with GA-map(TM) Dysbiosis Test (Genetic Analysis AS, Oslo, Norway). The test result was given as dysbiosis (yes/no). Comparisons were made between four groups: subjects with IBS and morbid obesity (IBS+/MO+); subjects without IBS and with morbid obesity (IBS-/MO+); subjects with IBS and without morbid obesity (IBS+/MO-); and healthy volunteers (IBS-/MO-).The prevalence rates of dysbiosis in the groups IBS+/MO+, IBS-/MO+, IBS+/MO- and IBS-/MO- were 18/28 (64%), 45/71 (63%), 31/63 (49%) and 38/91 (42%). Dysbiosis was more prevalent in subjects with morbid obesity, both in those with and without IBS, than in healthy volunteers (p values .04 and .006). Used as a diagnostic test for IBS in subjects without morbid obesity, the positive and negative likelihood ratios (LR) were 1.18 (0.83-1.67) and 0.87 (0.65-1.18), respectively, and in subjects with morbid obesity the LR were 1.01 (95% CI: 0.73-1.41) and 0.98 (0.54-1.75) respectively. The dysbiosis test was unsuitable as a diagnostic test for IBS. Dysbiosis was statistically significantly associated with morbid obesity, but not with IBS.